Jorey Chernett, a ten percent owner of Oncology Institute, Inc. (NASDAQ: TOI), reported a purchase of 25,000 shares of the companys common stock on March 20, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission.
The shares were acquired at a weighted average price of $3.35, with transaction prices recorded between $3.33 and $3.35 per share. The aggregate value of the trade was $83,750. After the purchase, Chernetts direct holdings in Oncology Institute total 10,276,929 shares.
The insider purchase coincides with a period of strong market performance for the companys shares, which have appreciated 233% over the past year. InvestingPro commentary cited in the filing notes that, despite the run-up, the company was unprofitable over the trailing twelve months. InvestingPro analysis also characterizes TOI as appearing undervalued at current prices and assigns the stock a "GOOD" Financial Health score. The platforms Pro Research Report for TOI is available to subscribers for additional detail.
On the fundamental front, Oncology Institutes fourth-quarter 2025 results exceeded analyst expectations. The company reported diluted earnings per share of -$0.06, compared with a consensus forecast of -$0.09, representing a positive surprise of 33.33%. Reported revenue for the quarter was $141.96 million, above the anticipated $139.79 million. The earnings release did not announce any material mergers or acquisitions, and there were no notable analyst upgrades or downgrades accompanying the report.
These developments provide investors with contemporaneous information on insider activity and recent operational performance. The Form 4 filing documents the transaction detail, while the quarterly results illustrate the companys ability to outpace expectations on both EPS and revenue, even as it remains unprofitable on a trailing-twelve-month basis.
Key points
- Insider purchase: Jorey Chernett bought 25,000 shares on March 20, 2026, for $83,750 at an average price of $3.35 per share.
- Ownership and market context: Chernett now directly owns 10,276,929 shares; TOIs stock has risen 233% over the past year, though the company was unprofitable over the last twelve months.
- Recent results: Q4 2025 EPS of -$0.06 beat the -$0.09 estimate and revenue of $141.96 million exceeded forecasts of $139.79 million.
Risks and uncertainties
- Profitability risk - The company remains unprofitable over the trailing twelve months, which may continue to affect valuation and capital allocation decisions.
- Market performance dependency - The stocks substantial one-year gain may expose investors to heightened volatility if operational momentum slows.
- Analyst coverage limitations - The earnings release noted no significant analyst upgrades or downgrades, which could limit new information flow for market participants.